Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 376

Sort by

Sort Order Select

Journal Articles

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Blood blood.2025030149.

https://doi.org/10.1182/blood.2025030149

Published: 2025

Includes: Supplemental data

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Rita Tavarozzi, Marco Ladetto, Francesca Bonello, Umberto Vitolo, Pier Luigi Zinzani, Angela Ferrari, Beatrice Casadei, Matthew Ku, Luigi Marcheselli, Stefano Luminari

Blood (2025) 146 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2025-7096

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Alessandra Tucci, Yair Herishanu, Juan Dupont, Sarit Assouline, Lori Leslie, Thor Hoyer, Pier Luigi Zinzani, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2025-1801

Published: 2025

Journal Articles

SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease since diagnosis

Blood (2025) 146 (Supplement 1): 5557.

https://doi.org/10.1182/blood-2025-5557

Published: 2025

Journal Articles

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Carmine Deluca, Toby Eyre, Christine Ryan, Kami Maddocks, Pier Luigi Zinzani, Michael Beyer, Ben Johnson, Abigail Brugger, Jessica Massey, Andrea Corti

Blood (2025) 146 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2025-2869

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea

Francesca Palandri, Filippo Branzanti, Alessandra Dedola, Chiara Sartor, Pier Luigi Zinzani

Blood (2025) 146 (Supplement 1): 3807.

https://doi.org/10.1182/blood-2025-3807

Published: 2025

Journal Articles

Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries

Massimo Breccia, Pier Paolo Olimpieri, Fabrizio Pane, Simone Celant, Alessandra Iurlo, Valentina Summa, Paolo Corradini, Pier Luigi Zinzani, Pierluigi Russo

Blood (2025) 146 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2025-3774

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma

Blood (2025) 146 (Supplement 1): 3918.

https://doi.org/10.1182/blood-2025-3918

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease since diagnosis

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea

Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only